MicroRNA-145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patients

Neoplasia (United States)

Volumn 15, Issue 2, 2013, Pages 218-230

  Doberstein, Kai ^a   Steinmeyer, Nico ^a   Hartmetz, Ann Kathrin ^a   Eberhardt, Wolfgang ^a   Mittelbronn, Michel ^b   Harter, Patrick N ^b   Juengel, Eva ^a   Blaheta, Roman ^a   Pfeilschifter, Josef ^a   Gutwein, Paul ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 145; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

3' UNTRANSLATED REGION; ARTICLE; CELL CYCLE; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KIDNEY CARCINOMA; METHYLATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

EID: 84873508717     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.121222     Document Type: Article

References (65)

1. McLaughlin JK and Lipworth L (2000). Epidemiologic aspects of renal cell cancer. Semin Oncol 27, 115-123.
2. Campbell SC, Flanigan RC, and Clark JI (2003). Nephrectomy in metastatic renal cell carcinoma. Curr Treat Options Oncol 4, 363-372.
3. Lendeckel U, Kohl J, Arndt M, Carl-McGrath S, Donat H, and Rocken C (2005). Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. J Cancer Res Clin Oncol 131, 41-48.
4. Zheng X, Jiang F, Katakowski M, Kalkanis SN, Hong X, Zhang X, Zhang ZG, Yang H, and Chopp M (2007). Inhibition of ADAM17 reduces hypoxia-induced brain tumor cell invasiveness. Cancer Sci 98, 674-684.
5. Blanchot-Jossic F, Jarry A, Masson D, Bach-Ngohou K, Paineau J, Denis MG, Laboisse CL, and Mosnier JF (2005). Up-regulated expression of ADAM17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells. J Pathol 207, 156-163.
6. Ding X, Yang LY, Huang GW, Wang W, and Lu WQ (2004). ADAM17 mRNA expression and pathological features of hepatocellular carcinoma. World J Gastroenterol 10, 2735-2739.
7. Zhou BB, Peyton M, He B, Liu C, Girard L, Caudler E, Lo Y, Baribaud F, Mikami I, Reguart N, et al. (2006). Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 10, 39-50.
8. Tanaka Y, Miyamoto S, Suzuki SO, Oki E, Yagi H, Sonoda K, Yamazaki A, Mizushima H, Maehara Y, Mekada E, et al. (2005). Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer. Clin Cancer Res 11, 4783-4792.
9. Ringel J, Jesnowski R, Moniaux N, Luttges J, Choudhury A, Batra SK, Kloppel G, and Lohr M (2006). Aberrant expression of a disintegrin and metalloproteinase 17/ tumor necrosis factor-α converting enzyme increases the malignant potential in human pancreatic ductal adenocarcinoma. Cancer Res 66, 9045-9053.
10. Sinnathamby G, Zerfass J, Hafner J, Block P, Nickens Z, Hobeika A, Secord AA, Lyerly HK, Morse MA, and Philip R (2011). ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers. Clin Exp Immunol 163, 324-332.
11. Roemer A, Schwettmann L, Jung M, Stephan C, Roigas J, Kristiansen G, Loening SA, Lichtinghagen R, and Jung K (2004). The membrane proteases adams and hepsin are differentially expressed in renal cell carcinoma. Are they potential tumor markers? J Urol 172, 2162-2166.
12. Bell JH, Herrera AH, Li Y, and Walcheck B (2007). Role of ADAM17 in the ectodomain shedding of TNF-α and its receptors by neutrophils and macrophages. J Leukoc Biol 82, 173-176.
13. Arribas J and Esselens C (2009). ADAM17 as a therapeutic target in multiple diseases. Curr Pharm Des 15, 2319-2335.
14. Franovic A, Robert I, Smith K, Kurban G, Pause A, Gunaratnam L, and Lee S (2006). Multiple acquired renal carcinoma tumor capabilities abolished upon silencing of ADAM17. Cancer Res 66, 8083-8090.
15. Scheller J, Chalaris A, Garbers C, and Rose-John S (2011). ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol 32, 380-387.
16. Kim D, Song J, Kim S, Kang SS, and Jin EJ (2011). MicroRNA-142-3p regulates TGF-β3-mediated region-dependent chondrogenesis by regulating ADAM9. Biochem Biophys Res Commun 414, 653-659.
17. Zhou C, Liu J, Li Y, Liu L, Zhang X, Ma CY, Hua SC, Yang M, and Yuan Q (2011). microRNA-1274a, a modulator of sorafenib induced a disintegrin and metalloproteinase 9 (ADAM9) down-regulation in hepatocellular carcinoma. FEBS Lett 585, 1828-1834.
18. Li H, Solomon E, Duhachek Muggy S, Sun D, and Zolkiewska A (2011). Metalloprotease-disintegrin ADAM12 expression is regulated by Notch signaling via microRNA-29. J Biol Chem 286, 21500-21510.
19. Lu PY, Xie F, and Woodle MC (2005). In vivo application of RNA interference: from functional genomics to therapeutics. Adv Genet 54, 117-142.
20. Ciafre SA, Galardi S, Mangiola A, Ferracin M, Liu CG, Sabatino G, Negrini M, Maira G, Croce CM, and Farace MG (2005). Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 334, 1351-1358.
21. Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T, et al. (2011). MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol 59, 671-681.
22. Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, Muth AN, Lee TH, Miano JM, Ivey KN, and Srivastava D (2009). miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 460, 705-710.
23. Zhang C (2009). MicroRNA-145 in vascular smooth muscle cell biology: a new therapeutic target for vascular disease. Cell Cycle 8, 3469-3473.
24. Cheng Y, Liu X, Yang J, Lin Y, Xu DZ, Lu Q, Deitch EA, Huo Y, Delphin ES, and Zhang C (2009). MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ Res 105, 158-166.
25. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103, 2257-2261.
26. Ostenfeld MS, Bramsen JB, Lamy P, Villadsen SB, Fristrup N, Sorensen KD, Ulhoi B, Borre M, Kjems J, Dyrskjot L, et al. (2010). miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors. Oncogene 29, 1073-1084.
27. Dyrskjot L, Ostenfeld MS, Bramsen JB, Silahtaroglu AN, Lamy P, Ramanathan R, Fristrup N, Jensen JL, Andersen CL, Zieger K, et al. (2009). Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res 69, 4851-4860.
28. Wang Y and Lee CG (2009). MicroRNA and cancer-focus on apoptosis. J Cell Mol Med 13, 12-23.
29. Chiyomaru T, Enokida H, Tatarano S, Kawahara K, Uchida Y, Nishiyama K, Fujimura L, Kikkawa N, Seki N, and Nakagawa M (2010). miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer 102, 883-891.
30. Spizzo R, Nicoloso MS, Lupini L, Lu Y, Fogarty J, Rossi S, Zagatti B, Fabbri M, Veronese A, Liu X, et al. (2010). miR-145 participates with TP53 in a deathpromoting regulatory loop and targets estrogen receptor-α in human breast cancer cells. Cell Death Differ 17, 246-254.
31. Michael MZ, O'Connor SM, van Holst Pellekaan NG, Young GP, and James RJ (2003). Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 1, 882-891.
32. Sempere LF, Christensen M, Silahtaroglu A, Bak M, Heath CV, Schwartz G, Wells W, Kauppinen S, and Cole CN (2007). Altered microRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 67, 11612-11620.
33. Villadsen SB, Bramsen JB, Ostenfeld MS, Wiklund ED, Fristrup N, Gao S, Hansen TB, Jensen TI, Borre M, Orntoft TF, et al. (2012). The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer. Br J Cancer 106, 366-374.
34. Chen Z, Zeng H, Guo Y, Liu P, Pan H, Deng A, and Hu J (2010). miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. J Exp Clin Cancer Res 29, 151.
35. Xu N, Papagiannakopoulos T, Pan G, Thomson JA, and Kosik KS (2009). MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell 137, 647-658.
36. Xu Q, Liu LZ, Qian X, Chen Q, Jiang Y, Li D, Lai L, and Jiang BH (2012). MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res 40, 761-774.
37. Suh SO, Chen Y, Zaman MS, Hirata H, Yamamura S, Shahryari V, Liu J, Tabatabai ZL, Kakar S, Deng G, et al. (2011). MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer. Carcinogenesis 32, 772-778.
38. Zaman MS, Chen Y, Deng G, Shahryari V, Suh SO, Saini S, Majid S, Liu J, Khatri G, Tanaka Y, et al. (2010). The functional significance of microRNA- 145 in prostate cancer. Br J Cancer 103, 256-264.
39. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et al. (2007). MicroRNA signatures in human ovarian cancer. Cancer Res 67, 8699-8707.
40. Kent OA, Chivukula RR, Mullendore M, Wentzel EA, Feldmann G, Lee KH, Liu S, Leach SD, Maitra A, and Mendell JT (2010). Repression of the miR-143/ 145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes Dev 24, 2754-2759.
41. Gregersen LH, Jacobsen AB, Frankel LB, Wen J, Krogh A, and Lund AH (2010). MicroRNA-145 targets YES and STAT1 in colon cancer cells. PLoS One 5, e8836.
42. Gutwein P, Schramme A, Abdel-Bakky MS, Doberstein K, Hauser IA, Ludwig A, Altevogt P, Gauer S, Hillmann A, Weide T, et al. (2010). ADAM10 is expressed in human podocytes and found in urinary vesicles of patients with glomerular kidney diseases. J Biomed Sci 17, 3.
43. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, et al. (2005). Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33, e179.
44. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, and Tuschl T (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498.
45. Jorgensen S, Baker A, Moller S, and Nielsen BS (2010). Robust one-day in situ hybridization protocol for detection of microRNAs in paraffin samples using LNA probes. Methods 52, 375-381.
46. Gutwein P, Schramme A, Sinke N, Abdel-Bakky MS, Voss B, Obermuller N, Doberstein K, Koziolek M, Fritzsche F, Johannsen M, et al. (2009). Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients. Eur J Cancer 45, 478-489.
47. Mechtersheimer S, Gutwein P, Agmon-Levin N, Stoeck A, Oleszewski M, Riedle S, Postina R, Fahrenholz F, Fogel M, Lemmon V, et al. (2001). Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins. J Cell Biol 155, 661-673.
48. Lee SB, Schramme A, Doberstein K, Dummer R, Abdel-Bakky MS, Keller S, Altevogt P, Oh ST, Reichrath J, Oxmann D, et al. (2010). ADAM10 is upregulated in melanoma metastasis compared with primary melanoma. J Invest Dermatol 130, 763-773.
49. Lewis BP, Burge CB, and Bartel DP (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120, 15-20.
50. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M, et al. (2005). Combinatorial microRNA target predictions. Nat Genet 37, 495-500.
51. Enright AJ, John B, Gaul U, Tuschl T, Sander C, and Marks DS (2003). MicroRNA targets in Drosophila. Genome Biol 5, R1.
52. Huang Y, Dai Y, Yang J, Chen T, Yin Y, Tang M, Hu C, and Zhang L (2009). Microarray analysis of microRNA expression in renal clear cell carcinoma. Eur J Surg Oncol 35, 1119-1123.
53. White NM, Khella HW, Grigull J, Adzovic S, Youssef YM, Honey RJ, Stewart R, Pace KT, Bjarnason GA, Jewett MA, et al. (2011). miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215. Br J Cancer 105, 1741-1749.
54. Wu X, Weng L, Li X, Guo C, Pal SK, Jin JM, Li Y, Nelson RA, Mu B, Onami SH, et al. (2012). Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PLoS One 7, e35661.
55. Knepper MA (1994). The aquaporin family of molecular water channels. Proc Natl Acad Sci USA 91, 6255-6258.
56. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, and Stoffel M (2005). Silencing of microRNAs in vivo with 'antagomirs'. Nature 438, 685-689.
57. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, and Riccardi C (1991). A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139, 271-279.
58. Zhang J, Sun Q, Zhang Z, Ge S, Han ZG, and Chen WT (2012). Loss of microRNA-143/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop. Oncogene 32, 61-69.
59. Ban J, Jug G, Mestdagh P, Schwentner R, Kauer M, Aryee DN, Schaefer KL, Nakatani F, Scotlandi K, Reiter M, et al. (2011). Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma. Oncogene 30, 2173-2180.
60. Cohen HT and McGovern FJ (2005). Renal-cell carcinoma. N Engl J Med 353, 2477-2490.
61. Mochizuki S and Okada Y (2007). ADAMs in cancer cell proliferation and progression. Cancer Sci 98, 621-628.
62. Zhao L, Chen X, and Cao Y (2011). New role of microRNA: carcinogenesis and clinical application in cancer. Acta Biochim Biophys Sin (Shanghai) 43, 831-839.
63. Yin R, Zhang S, Wu Y, Fan X, Jiang F, Zhang Z, Feng D, Guo X, and Xu L (2011). microRNA-145 suppresses lung adenocarcinoma-initiating cell proliferation by targeting OCT4. Oncol Rep 25, 1747-1754.
64. Ferrell JE Jr (2002). Self-perpetuating states in signal transduction: positive feedback, double-negative feedback and bistability. Curr Opin Cell Biol 14, 140-148.
65. Pasquinelli AE (2012). MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet 13, 271-282.